等待開盤 09-09 09:30:00 美东时间
-0.278
-0.75%
Kalaris Therapeutics is enrolling treatment-naïve nAMD patients in a Phase 1 trial of TH103, a novel anti-VEGF agent designed for longer-lasting efficacy, with initial data expected in Q4 2025. The company reported $88.4M in cash as of June 2025, sufficient for operations into Q4 2026. Quarter-over-quarter increases in R&D and G&A expenses reflect ongoing clinical activities. Kalaris expanded its leadership with Kristine Curtiss as Senior Vice Pr...
08-13 12:00
An announcement from Sabio Holdings ( ($TSE:SBIO) ) is now available. Sabio Hol...
08-01 07:38
Sabio Holdings ( ($TSE:SBIO) ) has shared an update. Sabio Holdings has announc...
08-01 07:37
Sabio Holdings ( ($TSE:SBIO) ) has provided an update. Sabio Holdings has launc...
06-27 04:42
Standard BioTools Inc. has launched its inaugural Proteomics Roundtable Series, a virtual event program aimed at advancing discussions in the field of proteomics. The series features leading researchers and experts sharing insights on breakthroughs, technological developments, and real-world applications impacting healthcare. The first session, "Is More Really More? Evaluating the Case for High-Plex, High-Quality Proteomics," takes place on June ...
05-30 11:00
Sabio Holdings ( ($TSE:SBIO) ) has issued an update. Sabio Holdings announced t...
05-15 01:39
An announcement from Sabio Holdings ( ($TSE:SBIO) ) is now available. Sabio Hol...
03-18 07:38
Atrium Research analyst Nicholas Cortellucci maintained a Buy rating on Sabio H...
02-18 23:55
Sabio Holdings ( ($TSE:SBIO) ) has issued an update. Sabio Holdings has launche...
01-31 01:42
根据国际权威指数公司MSCI(明晟)日前最新公布的评级结果,2024年三生制药MSCI ESG评级连续第三年稳居AA级,保持全球同业领先地位。 MSC...
2024-11-13 19:17